Revenues Working Against Amicogen, Inc.’s (KOSDAQ:092040) Share Price
Amicogen, Inc.’s (KOSDAQ:092040) price-to-sales (or “P/S”) ratio of 1.5x might make it look like a strong buy right now compared to the Biotechs industry in Korea, where around half of the companies have P/S ratios above 9.5x and even P/S above 49x are quite common. Nonetheless, we’d need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
See our latest analysis for Amicogen
What Does Amicogen’s Recent Performance Look Like?
It looks like revenue growth has deserted Amicogen recently, which is not something to boast about. One possibility is that the P/S is low because investors think this benign revenue growth rate…
